The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Open accessAbstract
Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease. Moreover, alpha-synuclein is present in Lewy-bodies, the neuropathological hallmark of PD, and the protein and its aggregation have been widely linked to neurotoxic pathways that ultimately lead to neurodegeneration. Such pathways include autophagy/lysosomal dysregulation, synaptic dysfunction, mitochondrial disruption, and endoplasmic reticulum (ER) and oxidative stress. Alpha-synuclein has not only been shown to alter cellular pathways but also to spread between cells, causing aggregation in host cells. Therapeutic approaches will need to address several, if not all, of these angles of alpha-synuclein toxicity. Here we review the current advances in therapeutic efforts for PD that aim to produce a disease-modifying therapy by targeting the spread, production, aggregation, and degradation of alpha-synuclein. These include: receptor blocking strategies whereby putative alpha-synuclein receptors could be blocked inhibiting alpha-synuclein spread, an alpha-synuclein reduction which will decrease the amount alpha-synuclein available for aggregation and pathway disruption, the use of small molecules in order to target alpha-synuclein aggregation, immunotherapy and the increase of alpha-synuclein degradation by increasing autophagy/lysosomal flux. The research discussed here may lead to a disease-modifying therapy that tackles disease onset and progression in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019338 · Cited by 423
RetractedCrews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · cited 2×
“Subsequently, α-syn was identified as a major component of LBs and LNs (Spillantini et al., 1997).”
BackgroundMutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Mitochondria: In Sickness and in Health
Nunnari, J., & Suomalainen, A. (2012) · Cell · doi:10.1016/j.cell.2012.02.035 · Cited by 3,479
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
WISEMAN, H., & HALLIWELL, B. (1996) · Biochemical Journal · doi:10.1042/bj3130017 · Cited by 2,345
Endoplasmic reticulum stress: cell life and death decisions
Xu, C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26373 · Cited by 2,255
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,132
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024 · cited 1×
“In addition, A53T and A30P α-syn exhibit a stronger binding affinity for the lysosomal receptor LAMP2A compared with wild-type (WT) α-syn, so these mutant forms of α-syn are not efficiently degraded by protein clearance mechanisms, which results in increased α-syn burden of chaperone-mediated autophagy and inhibits th…”
BackgroundLi, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
Kim, I., Xu, W., & Reed, J. C. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2755 · Cited by 1,817
α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Südhof, T. C. (2010) · Science · doi:10.1126/science.1195227 · Cited by 1,812
Normal oxidative damage to mitochondrial and nuclear DNA is extensive.
Richter, C., Park, J. W., & Ames, B. N. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.17.6465 · Cited by 1,725
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal
Maroteaux, L., Campanelli, J., & Scheller, R. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-08-02804.1988 · Cited by 1,641
The many faces of α-synuclein: from structure and toxicity to therapeutic target
Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3406 · Cited by 1,622
Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes
Davidson, W. S., Jonas, A., Clayton, D. F., & George, J. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.9443 · Cited by 1,585
Calcium and ROS: A mutual interplay
Görlach, A., Bertram, K., Hudecova, S., & Krizanova, O. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.010 · Cited by 1,546
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.
Uéda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D. A., Kondo, J., Ihara, Y., & Saitoh, T. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.11282 · Cited by 1,480
Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases
Chen, H., & Chan, D. C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp326 · Cited by 1,458
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy‐Agid, F., Agid, Y., Lees, A., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351 · cited 1×
“5–1% among individuals 65–69 years of age, rising to 1–3% among persons 80 years of age and older (Nussbaum and Ellis, 2003).”
BackgroundMazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263 · cited 1×
“Although the majority of studies suggest that cytosolic α-syn is present within cells as an intrinsically unfolded monomer, alternative hypotheses have proposed that it exists as a tetrameric alpha-helical oligomer that is resistant to fibrillization and thus distinct from pathological variants (Bartels et al., 2011;…”
BackgroundGoedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Sarkar, S., Davies, J. E., Huang, Z., Tunnacliffe, A., & Rubinsztein, D. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609532200 · Cited by 1,142
α-Synuclein strains cause distinct synucleinopathies after local and systemic administration
Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., & Baekelandt, V. (2015) · Nature · doi:10.1038/nature14547 · Cited by 1,130 · cited 2×
“While numerous lines of evidence indicate that monomeric α-syn is not toxic, several studies highlight α-syn oligomers and fibrils as the species responsible for α-syn toxicity (Neumann et al., 2004; Outeiro et al., 2008; Peelaerts et al., 2015), and it has been shown that overexpression or triplication of synuclein i…”
BackgroundLuk, K. C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M. Y. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112457 · Cited by 1,100
Eliezer, D., Kutluay, E., Bussell, R., & Browne, G. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4538 · Cited by 1,090
Giasson, B. I., Murray, I. V. J., Trojanowski, J. Q., & Lee, V. M.-Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008919200 · Cited by 1,080
Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G., & Anandatheerthavarada, H. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710012200 · Cited by 1,080
Identification of two distinct synucleins from human brain
Jakes, R., Spillantini, M. G., & Goedert, M. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00395-5 · Cited by 1,080
Grazia Spillantini, M., Anthony Crowther, R., Jakes, R., Cairns, N. J., Lantos, P. L., & Goedert, M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00504-7 · Cited by 1,025
Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein
Tuttle, M. D., Comellas, G., Nieuwkoop, A. J., Covell, D. J., Berthold, D. A., Kloepper, K. D., Courtney, J. M., Kim, J. K., Barclay, A. M., Kendall, A., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3194 · Cited by 959
Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T. M., Milton, S. C., Hall, J. E., & Glabe, C. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400260200 · Cited by 902
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Prion-like spreading of pathological α-synuclein in brain
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D. M. A., & Hasegawa, M. (2013) · Brain · doi:10.1093/brain/awt037 · Cited by 867
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859 · cited 1×
“PD is characterized by motor symptoms including tremor, rigidity, bradykinesia, postural instability, gait and balance impairment and non-motor symptoms such as cognitive decline, autonomic impairment, rapid eye movement behavioral sleep disorder, constipation, and other behavioral disturbances (Stacy, 2011; Obeso et…”
BackgroundHeparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds
Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., Ouidja, M. O., Brodsky, F. M., Marasa, J., Bagchi, D. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301440110 · Cited by 859
Vagotomy and subsequent risk of Parkinson's disease
Svensson, E., Horváth‐Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015) · Annals of Neurology · doi:10.1002/ana.24448 · Cited by 806
Spreading of pathology in neurodegenerative diseases: a focus on human studies
Brettschneider, J., Tredici, K. D., Lee, V. M.-Y., & Trojanowski, J. Q. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3887 · Cited by 790
Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
Polymeropoulos, M. H., Higgins, J. J., Golbe, L. I., Johnson, W. G., Ide, S. E., Di Iorio, G., Sanges, G., Stenroos, E. S., Pho, L. T., Schaffer, A. A., et al. (1996) · Science · doi:10.1126/science.274.5290.1197 · Cited by 788 · cited 1×
“Several decades later, in 1996, the first link between α-syn and the PD phenotype was established with the identification of the A53T point mutation on chromosome 4q21-23 (Polymeropoulos et al., 1996).”
BackgroundTFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity
Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., & Björklund, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305623110 · Cited by 753
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah, G. E., Brahmachari, S., Shin, J.-H., et al. (2016) · Science · doi:10.1126/science.aah3374 · Cited by 690
Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism
Prusiner, S. B., Woerman, A. L., Mordes, D. A., Watts, J. C., Rampersaud, R., Berry, D. B., Patel, S., Oehler, A., Lowe, J. K., Kravitz, S. N., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514475112 · Cited by 689
Recasens, A., Dehay, B., Bové, J., Carballo‐Carbajal, I., Dovero, S., Pérez‐Villalba, A., Fernagut, P., Blesa, J., Parent, A., Perier, C., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24066 · Cited by 632
α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease
Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C. T., Burton, E. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3634 · Cited by 619
Fauvet, B., Mbefo, M. K., Fares, M.-B., Desobry, C., Michael, S., Ardah, M. T., Tsika, E., Coune, P., Prudent, M., Lion, N., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.318949 · Cited by 566
LRRK2 activation in idiopathic Parkinson’s disease
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5429 · Cited by 564
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
Fighting neurodegeneration with rapamycin: mechanistic insights
Bové, J., Martínez-Vicente, M., & Vila, M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3068 · Cited by 525
New insights into autophagosome–lysosome fusion
Nakamura, S., & Yoshimori, T. (2017) · Journal of Cell Science · doi:10.1242/jcs.196352 · Cited by 518
Hsp70 Reduces α-Synuclein Aggregation and Toxicity
Klucken, J., Shin, Y., Masliah, E., Hyman, B. T., & McLean, P. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400255200 · Cited by 508
Przedborski, S., Jackson‐Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R., & Akram, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00183.x · Cited by 507
Volles, M. J., & Lansbury, P. T. (2002) · Biochemistry · doi:10.1021/bi0121353 · Cited by 487
A soluble α-synuclein construct forms a dynamic tetramer
Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L. T. T., Liao, J., Auclair, J. R., Johnson, D., Landeru, A., Simorellis, A. K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113260108 · Cited by 478
Burré, J., Sharma, M., & Südhof, T. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416598111 · Cited by 477
The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils
Zhu, M., Rajamani, S., Kaylor, J., Han, S., Zhou, F., & Fink, A. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403129200 · Cited by 473
Rego, A. C., & Oliveira, C. R. (2003) · Neurochemical Research · doi:10.1023/a:1025682611389 · Cited by 472
Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., Prix, C., Pan-Montojo, F., Bertsch, U., Mitteregger-Kretzschmar, G., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1114-9 · Cited by 457
Floor, E., & Wetzel, M. G. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70010268.x · Cited by 452
Mendez, I., Viñuela, A., Astradsson, A., Mukhida, K., Hallett, P., Robertson, H., Tierney, T., Holness, R., Dagher, A., Trojanowski, J. Q., et al. (2008) · Nature Medicine · doi:10.1038/nm1752 · Cited by 443
Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions
Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V. M.-Y., Trojanowski, J. Q., Mann, D., & Iwatsubo, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208046200 · Cited by 428
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Bussell, R., & Eliezer, D. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00520-5 · Cited by 418
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease
Mittal, S., Bjørnevik, K., Im, D. S., Flierl, A., Dong, X., Locascio, J. J., Abo, K. M., Long, E., Jin, M., Xu, B., et al. (2017) · Science · doi:10.1126/science.aaf3934 · Cited by 416
Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., Hyman, B. T., & McLean, P. J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001867 · Cited by 401
Mazzulli, J. R., Zunke, F., Isacson, O., Studer, L., & Krainc, D. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520335113 · Cited by 386
A critical evaluation of the Braak staging scheme for Parkinson's disease
Burke, R. E., Dauer, W. T., & Vonsattel, J. P. G. (2008) · Annals of Neurology · doi:10.1002/ana.21541 · Cited by 377
Oueslati, A. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160779 · Cited by 375
Small Molecule Inhibitors of α-Synuclein Filament Assembly
Masuda, M., Suzuki, N., Taniguchi, S., Oikawa, T., Nonaka, T., Iwatsubo, T., Hisanaga, S.-I., Goedert, M., & Hasegawa, M. (2006) · Biochemistry · doi:10.1021/bi0600749 · Cited by 365
Smith, W. W., Jiang, H., Pei, Z., Tanaka, Y., Morita, H., Sawa, A., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi396 · Cited by 365
Properties of native brain α-synuclein
Burré, J., Vivona, S., Diao, J., Sharma, M., Brunger, A. T., & Südhof, T. C. (2013) · Nature · doi:10.1038/nature12125 · Cited by 339
Alpha-synuclein oligomers: a new hope
Bengoa-Vergniory, N., Roberts, R. F., Wade-Martins, R., & Alegre-Abarrategui, J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1755-1 · Cited by 338
Self-citationA mitochondrial superoxide theory for oxidative stress diseases and aging
Indo, H. P., Yen, H.-C., Nakanishi, I., Matsumoto, K.-I., Tamura, M., Nagano, Y., Matsui, H., Gusev, O., Cornette, R., Okuda, T., et al. (2015) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.14-42 · Cited by 334
Colla, E., Jensen, P. H., Pletnikova, O., Troncoso, J. C., Glabe, C., & Lee, M. K. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5368-11.2012 · Cited by 323
Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium
Alafuzoff, I., Ince, P. G., Arzberger, T., Al-Sarraj, S., Bell, J., Bodi, I., Bogdanovic, N., Bugiani, O., Ferrer, I., Gelpi, E., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0523-2 · Cited by 322
Jankovic, J., Goodman, I., Safirstein, B., Marmon, T. K., Schenk, D. B., Koller, M., Zago, W., Ness, D. K., Griffith, S. G., Grundman, M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1487 · Cited by 301
Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking
Choi, B.-K., Choi, M.-G., Kim, J.-Y., Yang, Y., Lai, Y., Kweon, D.-H., Lee, N. K., & Shin, Y.-K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218424110 · Cited by 300
Sinha, S., Lopes, D. H. J., Du, Z., Pang, E. S., Shanmugam, A., Lomakin, A., Talbiersky, P., Tennstaedt, A., McDaniel, K., Bakshi, R., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja206279b · Cited by 299
The vermiform appendix impacts the risk of developing Parkinson’s disease
Killinger, B. A., Madaj, Z., Sikora, J. W., Rey, N., Haas, A. J., Vepa, Y., Lindqvist, D., Chen, H., Thomas, P. M., Brundin, P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5280 · Cited by 279
Protein phosphorylation in neurodegeneration: friend or foe?
Tenreiro, S., Eckermann, K., & Outeiro, T. F. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00042 · Cited by 252
First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers
Schenk, D. B., Koller, M., Ness, D. K., Griffith, S. G., Grundman, M., Zago, W., Soto, J., Atiee, G., Ostrowitzki, S., & Kinney, G. G. (2017) · Movement Disorders · doi:10.1002/mds.26878 · Cited by 252
Brustovetsky, N., Brustovetsky, T., Jemmerson, R., & Dubinsky, J. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00671.x · Cited by 246
Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease
Hashimoto, M., Takeda, A., Hsu, L. J., Takenouchi, T., & Masliah, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.41.28849 · Cited by 236
A critical reappraisal of current staging of Lewy-related pathology in human brain
Jellinger, K. A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0406-y · Cited by 230
Soluble Amyloid Oligomers Increase Bilayer Conductance by Altering Dielectric Structure
Sokolov, Y., Kozak, J. A., Kayed, R., Chanturiya, A., Glabe, C., & Hall, J. E. (2006) · The Journal of General Physiology · doi:10.1085/jgp.200609533 · Cited by 228
mTOR: on target for novel therapeutic strategies in the nervous system
Maiese, K., Chong, Z. Z., Shang, Y. C., & Wang, S. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.11.001 · Cited by 223
In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration
Gorbatyuk, O. S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A. S., Sullivan, L. F., Mandel, R. J., Chen, W., Meyers, C., Manfredsson, F. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.115 · Cited by 213
Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment
Poehler, A.-M., Xiang, W., Spitzer, P., May, V. E. L., Meixner, H., Rockenstein, E., Chutna, O., Outeiro, T. F., Winkler, J., Masliah, E., et al. (2014) · Autophagy · doi:10.4161/auto.36436 · Cited by 212
Parihar, M. S., Parihar, A., Fujita, M., Hashimoto, M., & Ghafourifar, P. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.05.008 · Cited by 206
Anwar, S., Peters, O., Millership, S., Ninkina, N., Doig, N., Connor-Robson, N., Threlfell, S., Kooner, G., Deacon, R. M., Bannerman, D. M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6194-10.2011 · Cited by 200
Self-citationRandomized phase I clinical trial of anti–α‐synuclein antibody BIIB054
Brys, M., Fanning, L., Hung, S., Ellenbogen, A., Penner, N., Yang, M., Welch, M., Koenig, E., David, E., Fox, T., et al. (2019) · Movement Disorders · doi:10.1002/mds.27738 · Cited by 200
Weihofen, A., Liu, Y., Arndt, J. W., Huy, C., Quan, C., Smith, B. A., Baeriswyl, J.-L., Cavegn, N., Senn, L., Su, L., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.10.016 · Cited by 195
Effect of 4-Hydroxy-2-nonenal Modification on α-Synuclein Aggregation
Qin, Z., Hu, D., Han, S., Reaney, S. H., Di Monte, D. A., & Fink, A. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608126200 · Cited by 191
Ghosh, A., Tyson, T., George, S., Hildebrandt, E. N., Steiner, J. A., Madaj, Z., Schulz, E., Machiela, E., McDonald, W. G., Escobar Galvis, M. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2210 · Cited by 189
Mitochondrial translocation of α-synuclein is promoted by intracellular acidification
Cole, N. B., DiEuliis, D., Leo, P., Mitchell, D. C., & Nussbaum, R. L. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.03.012 · Cited by 185
Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
West, A. B. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.019 · Cited by 176
Zambon, F., Cherubini, M., Fernandes, H. J. R., Lang, C., Ryan, B. J., Volpato, V., Bengoa‐Vergniory, N., Vingill, S., Attar, M., Booth, H., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz038 · Cited by 174
Self-citationSilencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi
Sapru, M. K., Yates, J. W., Hogan, S., Jiang, L., Halter, J., & Bohn, M. C. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.12.024 · Cited by 173
Samuel, F., Flavin, W. P., Iqbal, S., Pacelli, C., Sri Renganathan, S. D., Trudeau, L.-E., Campbell, E. M., Fraser, P. E., & Tandon, A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.705095 · Cited by 169
Senior, S. L., Ninkina, N., Deacon, R., Bannerman, D., Buchman, V. L., Cragg, S. J., & Wade‐Martins, R. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06055.x · Cited by 164
Self-citationA Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo
Prabhudesai, S., Sinha, S., Attar, A., Kotagiri, A., Fitzmaurice, A. G., Lakshmanan, R., Ivanova, M. I., Loo, J. A., Klärner, F.-G., Schrader, T., et al. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0105-1 · Cited by 161
Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
Ghiglieri, V., Calabrese, V., & Calabresi, P. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00295 · Cited by 159
α-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
McCormack, A. L., Mak, S. K., Henderson, J. M., Bumcrot, D., Farrer, M. J., & Di Monte, D. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012122 · Cited by 158
A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease
Wrasidlo, W., Tsigelny, I. F., Price, D. L., Dutta, G., Rockenstein, E. M., Schwarz, T. C., Ledolter, K., Bonhaus, D. W., Paulino, A., Eleuteri, S., et al. (2016) · Brain · doi:10.1093/brain/aww238 · Cited by 158
In vivo silencing of alpha-synuclein using naked siRNA
Lewis, J. M., Melrose, H. L., Bumcrot, D. A., Hope, A. D., Zehr, C., Lincoln, S., Braithwaite, A. T., He, Z., Ogholikhan, S., Hinkle, K. M., et al. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-19 · Cited by 157
Raised calcium promotes α-synuclein aggregate formation
Nath, S., Goodwin, J., Engelborghs, Y., & Pountney, D. L. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.12.004 · Cited by 154
Treatments for Parkinson disease—past achievements and current clinical needs
Poewe, W. H. (2009) · Neurology · doi:10.1212/wnl.0b013e31819908ce · Cited by 152
New insights into the role of mitochondrial calcium homeostasis in cell migration
Paupe, V., & Prudent, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.039 · Cited by 152
Braak, H., & Tredici, K. D. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023630 · Cited by 151
Molecular tweezers for lysine and arginine – powerful inhibitors of pathologic protein aggregation
Schrader, T. H., Bitan, G., & Klärner, F. (2016) · Chemical Communications · doi:10.1039/c6cc04640a · Cited by 150
Alarcón-Arís, D., Recasens, A., Galofré, M., Carballo‐Carbajal, I., Zacchi, N., Ruiz‐Bronchal, E., Pavia-Collado, R., Chica, R., Ferrés‐Coy, A., Santos, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.015 · Cited by 149
Helix periodicity, topology, and dynamics of membrane‐associated α‐Synuclein
Bussell, R., Ramlall, T. F., & Eliezer, D. (2005) · Protein Science · doi:10.1110/ps.041255905 · Cited by 147
Fountaine, T. M., & Wade‐Martins, R. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21125 · Cited by 145
Self-citationBae, E.-J., Ho, D. H., Park, E., Jung, J. W., Cho, K., Hong, J. H., Lee, H.-J., Kim, K. P., & Lee, S. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4429 · Cited by 136
Levin, J., Schmidt, F., Boehm, C., Prix, C., Bötzel, K., Ryazanov, S., Leonov, A., Griesinger, C., & Giese, A. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1265-3 · Cited by 132
Explaining the Structural Plasticity of α-Synuclein
Ullman, O., Fisher, C. K., & Stultz, C. M. (2011) · Journal of the American Chemical Society · doi:10.1021/ja208657z · Cited by 129
A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed α-synuclein
Zhou, C., Emadi, S., Sierks, M. R., & Messer, A. C. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.019 · Cited by 128
Autophagosome dynamics in neurodegeneration at a glance
Wong, Y. C., & Holzbaur, E. L. F. (2015) · Journal of Cell Science · doi:10.1242/jcs.161216 · Cited by 126
Collier, T. J., Redmond, D. E., Steece‐Collier, K., Lipton, J. W., & Manfredsson, F. P. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00012 · Cited by 125
Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice
Sacino, A. N., Brooks, M., Thomas, M. A., McKinney, A. B., McGarvey, N. H., Rutherford, N. J., Ceballos‐Diaz, C., Robertson, J., Golde, T. E., & Giasson, B. I. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1268-0 · Cited by 123
Guilliams, T., El-Turk, F., Buell, A. K., O’Day, E. M., Aprile, F. A., Esbjörner, E. K., Vendruscolo, M., Cremades, N., Pardon, E., Wyns, L., et al. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.01.040 · Cited by 122
Sinha, S., Du, Z., Maiti, P., Klärner, F., Schrader, T. H., Wang, C., & Bitan, G. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200133x · Cited by 122
The Interplay between Alpha-Synuclein Clearance and Spreading
da Fonseca, T. L., Villar‐Piqué, A., & Outeiro, T. F. (2015) · Biomolecules · doi:10.3390/biom5020435 · Cited by 121
Cox, D., Selig, E. E., Griffin, M. D. W., Carver, J. A., & Ecroyd, H. W. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.739250 · Cited by 121
Sánchez-Guajardo, V., Annibali, A., Jensen, P. H., & Romero‐Ramos, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31829768d2 · Cited by 117
Prion-like propagation of pathology in Parkinson disease
Volpicelli‐Daley, L. A., & Brundin, P. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63945-5.00017-9 · Cited by 116
Jiang, P., Gan, M., Yen, S.-H., McLean, P. J., & Dickson, D. W. (2017) · Scientific Reports · doi:10.1038/s41598-017-08149-w · Cited by 115
Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration
Jeong, G. R., Jang, E.-H., Bae, J. R., Jun, S., Kang, H. C., Park, C., Shin, J., Yamamoto, Y., Tanaka, K., Dawson, V. L., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0240-1 · Cited by 112
Loss of Functional Alpha-Synuclein: A Toxic Event in Parkinson's Disease?
Kanaan, N. M., & Manfredsson, F. P. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-012138 · Cited by 109
Molecular Basis for Preventing α-Synuclein Aggregation by a Molecular Tweezer
Acharya, S., Safaie, B. M., Wongkongkathep, P., Ivanova, M. I., Attar, A., Klärner, F. G., Schrader, T. H., Loo, J. A., Bitan, G., & Lapidus, L. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.524520 · Cited by 101
Selective vulnerability in α-synucleinopathies
Alegre‐Abarrategui, J., Brimblecombe, K. R., Roberts, R. F., Velentza‐Almpani, E., Tilley, B. S., Bengoa‐Vergniory, N., & Proukakis, C. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02010-2 · Cited by 97
Self-citationJelliffe (1911) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-191105000-00015 · Cited by 80
Sorrentino, Z. A., Brooks, M. M. T., Hudson, V., Rutherford, N. J., Golde, T. E., Giasson, B. I., & Chakrabarty, P. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0182-z · Cited by 79
Widespread and abundant α‐synuclein pathology in a neurologically unimpaired subject
Parkkinen, L., Pirttilä, T., Tervahauta, M., & Alafuzoff, I. I. (2005) · Neuropathology · doi:10.1111/j.1440-1789.2005.00644.x · Cited by 77
Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders
Hasegawa, M., Nonaka, T., & Masuda‐Suzukake, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.010 · Cited by 76
Deeg, A. A., Reiner, A. M., Schmidt, F., Schueder, F., Ryazanov, S., Ruf, V., Giller, K., Becker, S., Leonov, A., Griesinger, C., et al. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.05.021 · Cited by 75
Nonmotor Symptoms in Parkinson's Disease
Stacy, M. A. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2011.620196 · Cited by 75
Regional Distribution of Proteinase K-Resistant α-Synuclein Correlates with Lewy Body Disease Stage
Neumann, M., Müller, V., Kretzschmar, H. A., Haass, C., & Kahle, P. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.12.1225 · Cited by 73
A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein
Richter, F., Subramaniam, S., Magen, I., Lee, P., Hayes, J., Attar, A., Zhu, C., Franich, N. R., Bove, N., Rosa, K. D. L., et al. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0544-9 · Cited by 61
Phenotypic variability of PINK1 expression: 12 Years' clinical follow‐up of two Italian families
Ricciardi, L., Petrucci, S., Guidubaldi, A., Ialongo, T., Serra, L., Ferraris, A., Spanò, B., Bozzali, M., Valente, E. M., & Bentivoglio, A. R. (2014) · Movement Disorders · doi:10.1002/mds.25994 · Cited by 57
Association of α-Synuclein and Mutants with Lipid Membranes: Spin-Label ESR and Polarized IR
Ramakrishnan, M., Jensen, P. H., & Marsh, D. (2006) · Biochemistry · doi:10.1021/bi052344d · Cited by 56
Attar, A., Chan, W.-T. C., Klärner, F., Schrader, T. H., & Bitan, G. (2014) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-15-23 · Cited by 56
A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses
Zha, J., Liu, X., Zhu, J., Liu, S., Lü, S., Xu, P., Yu, X., & Liu, R. (2016) · Scientific Reports · doi:10.1038/srep36631 · Cited by 55
Liu, Y., Sorce, S., Nuvolone, M., Domange, J., & Aguzzi, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-32712-8 · Cited by 54
α-Synuclein Conformation Affects Its Tyrosine-Dependent Oxidative Aggregation
Ruf, R. A. S., Lutz, E. A., Zigoneanu, I. G., & Pielak, G. J. (2008) · Biochemistry · doi:10.1021/bi801884z · Cited by 45
Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies
Kaufman, S. K., & Diamond, M. I. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0196-3 · Cited by 44
Schwab, K., Frahm, S., Horsley, D., Rickard, J. E., Melis, V., Goatman, E. A., Magbagbeolu, M., Douglas, M., Leith, M., Baddeley, T. C., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00447 · Cited by 33
Smaldone, G., Diana, D., Pollegioni, L., Gaetano, S. D., Fattorusso, R., & Pedone, E. M. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.02.012 · Cited by 9
Cited by
Trial of Cinpanemab in Early Parkinson’s Disease
Lang, A. E., Siderowf, A. D., Macklin, E. A., Poewe, W., Brooks, D. J., Fernandez, H. H., Rascol, O., Giladi, N., Stocchi, F., Tanner, C. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203395 · Cited by 351
The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases
Rozpędek-Kamińska, W., Siwecka, N., Wawrzynkiewicz, A., Wojtczak, R., Pytel, D., Diehl, J. A., & Majsterek, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062108 · Cited by 84
Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease
Kasen, A., Houck, C., Burmeister, A. R., Sha, Q., Brundin, L., & Brundin, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105654 · Cited by 78
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Limegrover, C. S., Yurko, R., Izzo, N. J., LaBarbera, K. M., Rehak, C., Look, G., Rishton, G., Safferstein, H., & Catalano, S. M. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24782 · Cited by 43
Metadata
- Authors
- Fields, C. R., Bengoa-Vergniory, N., & Wade-Martins, R.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-12-05
- Volume
- 12
- Pages
- 299-299
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2992485745
- Cited by
- 328
- References
- 160
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.